What we do Kopran Limited is an integrated pharmaceutical company manufacturing high-quality formulations and Active Pharmaceutical Ingredients (APIs) for global markets. |
Founded in 1,958 |
Market share Key player in penicillin and non-penicillin drugs, with strong export presence to over 50 countries. |
Problem solved Provides essential medicines and APIs to both regulated and non-regulated markets ensuring global drug availability and quality. |
Top clients or who we serve Serves pharmaceutical companies worldwide (B2B) and caters to global healthcare markets across multiple continents. |
Key management Surendra Somani - Chairman & Managing Director; Adarsh Somani - Director; Chandresh Gandhi - Independent Director; Mamta Biyani - Independent Director. |
Our journey and innovations Since 1958, expanded capacities, acquired international accreditations (US FDA, MHRA UK), and diversified into sterile cephalosporins, carbapenems, and formulations. |
Where we operate India (manufacturing and sales), exports to South Africa, Ethiopia, UK, Tanzania, Zambia, Chile, Hong Kong, Bangladesh, Russia, Jordan, Mexico, Switzerland, Germany, and others. |
Top products or what we offer APIs including atenolol, sterile carbapenems, cephalosporins; formulations spanning penicillin and non-penicillin oral dosage forms. |
Top brands SMYLE brand (merged subsidiary); Extensive portfolio with over 100 dosages in tablets, capsules, suspensions meeting international standards. |
Raw materials needed Basic chemicals for penicillin and non-penicillin drugs; intermediates for semi-synthetic antibiotics. |
Raw materials supplier Global chemical suppliers, including localized partners for backward integration. |
Recurring vs cyclical contribution Revenue is a mix of recurring sales in pharmaceuticals and APIs with steady demand across regulated markets. |
Our industry position Among top few fastest growing Indian pharmaceutical companies with strong export credentials and regulatory approvals. |
Financial highlights Consolidated revenue ₹633.6 crores FY 2024-25; net profit ₹38.55 crores; stable EBITDA despite market fluctuations. |
Geographical revenue split Domestic revenue approx. ₹202 crores; significant exports to Africa, Europe, Asia, Americas totaling over ₹400 crores. |
Order book - |
Whats driving growth Expansion in API portfolio, regulatory approvals, capacity enhancements, and growth in international markets. |
Our future plans Capacity expansion, new product launches, increased automation, and focus on R&D for niche APIs and formulations. |
Our green promise Committed to sustainability through efficient processes and CSR activities, details on website. |
Our people and values Employee stock option plan to retain key talent; inclusive work culture; strong governance practices. |
Key challenges ahead Regulatory compliance, competition from low-cost producers, raw material volatility, and global market dynamics. |
Interesting facts Awarded Quality Excellence by Indian Drug Manufacturers Association; one of India's early pharma companies with multi-continent approvals. |
Risks and strategy Mitigates regulatory and market risks via diversified product mix, global accreditations, and strong internal controls. |
